Experiments on CBA/CaLac mice showed that single and course administration of proproten-100 did not increase the percent of abnormal metaphases in red bone marrow cells and produced no genotoxic effects in Drosophila melanogaster wing cells in the test of somatic mosaicism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
A. G. Gofman, I. N. Pyatnickaya, Yu. V. Valentik, et al., Byull. Eksp. Biol. Med., Suppl. 1, 86–90 (2003).
A. D. Durnev, Yu. A. Revazova, O. L. Verstakova, et al., Manual on Experimental (Preclinical) Testing of New Pharmacological Agents [in Russian], Moscow (2005).
L. P. Zakharenko and I. K. Zakharov, Genetika, 32, No. 6, 755–758 (1996).
V. N. Orlov, G. A. Chudinovskaya, and E. P. Kryukova, Analysis of Chromosome Sets in Mammals [in Russian], Moscow (1976).
M. B. Shtark, O. I. Epshtein, and T. M. Vorob’eva, et al., Narkologiya, No. 3, 9 (2002).
O. I. Epshtein, M. B. Shtark, A. M. Dygai, et al., Pharmacology of Ultralow Doses of Antibodies to Endogenous Regulators of Functions [in Russian], Moscow (2005).
H. Frei and F. E. Wurgler, Mutat. Res. 203, No. 4, 297–308 (1988).
Author information
Authors and Affiliations
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 148, Suppl. 1, pp. 187–188, September, 2009
Rights and permissions
About this article
Cite this article
Voronova, O.L. Preclinical Study of Proproten-100 for Mutagenicity. Bull Exp Biol Med 148, 547–548 (2009). https://doi.org/10.1007/s10517-010-0761-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-010-0761-2